These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 12613516

  • 1. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies.
    Barosi G, Elliott M, Canepa L, Ballerini F, Piccaluga PP, Visani G, Marchetti M, Pozzato G, Zorat F, Tefferi A.
    Leuk Lymphoma; 2002 Dec; 43(12):2301-7. PubMed ID: 12613516
    [Abstract] [Full Text] [Related]

  • 2. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.
    Marchetti M, Barosi G, Balestri F, Viarengo G, Gentili S, Barulli S, Demory JL, Ilariucci F, Volpe A, Bordessoule D, Grossi A, Le Bousse-Kerdiles MC, Caenazzo A, Pecci A, Falcone A, Broccia G, Bendotti C, Bauduer F, Buccisano F, Dupriez B.
    J Clin Oncol; 2004 Feb 01; 22(3):424-31. PubMed ID: 14752066
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia.
    Barosi G, Grossi A, Comotti B, Musto P, Gamba G, Marchetti M.
    Br J Haematol; 2001 Jul 01; 114(1):78-83. PubMed ID: 11472348
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia.
    Mesa RA, Elliott MA, Schroeder G, Tefferi A.
    Mayo Clin Proc; 2004 Jul 01; 79(7):883-9. PubMed ID: 15244384
    [Abstract] [Full Text] [Related]

  • 7. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.
    Mesa RA, Steensma DP, Pardanani A, Li CY, Elliott M, Kaufmann SH, Wiseman G, Gray LA, Schroeder G, Reeder T, Zeldis JB, Tefferi A.
    Blood; 2003 Apr 01; 101(7):2534-41. PubMed ID: 12517815
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Thalidomide treatment in myelofibrosis with myeloid metaplasia.
    Elliott MA, Mesa RA, Li CY, Hook CC, Ansell SM, Levitt RM, Geyer SM, Tefferi A.
    Br J Haematol; 2002 May 01; 117(2):288-96. PubMed ID: 11972510
    [Abstract] [Full Text] [Related]

  • 10. Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
    Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL, Hogan WJ, Litzow MR, Allred JB, Jones D, Byrne C, Zeldis JB, Ketterling RP, McClure RF, Giles F, Kantarjian HM.
    Blood; 2006 Aug 15; 108(4):1158-64. PubMed ID: 16609064
    [Abstract] [Full Text] [Related]

  • 11. Thalidomide therapy for myelofibrosis with myeloid metaplasia.
    Thomas DA, Giles FJ, Albitar M, Cortes JE, Verstovsek S, Faderl S, O'Brien SM, Garcia-Manero G, Keating MJ, Pierce S, Zeldis J, Kantarjian HM.
    Cancer; 2006 May 01; 106(9):1974-84. PubMed ID: 16583431
    [Abstract] [Full Text] [Related]

  • 12. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study.
    Piccaluga PP, Visani G, Pileri SA, Ascani S, Grafone T, Isidori A, Malagola M, Finelli C, Martinelli G, Ricci P, Baccarani M, Tura S.
    Leukemia; 2002 Sep 01; 16(9):1609-14. PubMed ID: 12200671
    [Abstract] [Full Text] [Related]

  • 13. Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia.
    Merup M, Kutti J, Birgergård G, Mauritzson N, Björkholm M, Markevärn B, Maim C, Westin J, Palmblad J, Swedish National Study Group on Chronic Myeloproliferative Disorders.
    Med Oncol; 2002 Sep 01; 19(2):79-86. PubMed ID: 12180484
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Myelofibrosis with myeloid metaplasia. A study of 24 consecutive patients].
    Bettini R, Redaelli S, Marzetta K, Maino C, Sala D, Saccà V, Gorini M.
    Recenti Prog Med; 2004 Sep 01; 95(7-8):358-64. PubMed ID: 15303545
    [Abstract] [Full Text] [Related]

  • 16. Mini-dose of thalidomide for treatment of primary myelofibrosis. Report of a case with complete reversal of bone marrow fibrosis and splenomegaly.
    Berrebi A, Feldberg E, Spivak I, Shvidel L.
    Haematologica; 2007 Feb 01; 92(2):e15-6. PubMed ID: 17405746
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia.
    Barosi G, Viarengo G, Pecci A, Rosti V, Piaggio G, Marchetti M, Frassoni F.
    Blood; 2001 Dec 01; 98(12):3249-55. PubMed ID: 11719361
    [Abstract] [Full Text] [Related]

  • 19. rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia. Experience in 6 patients and meta-analytical approach.
    Rodríguez JN, Martino ML, Diéguez JC, Prados D.
    Haematologica; 1998 Jul 01; 83(7):616-21. PubMed ID: 9718866
    [Abstract] [Full Text] [Related]

  • 20. Thalidomide for the treatment of idiopathic myelofibrosis.
    Strupp C, Germing U, Scherer A, Kündgen A, Mödder U, Gattermann N, Haas R.
    Eur J Haematol; 2004 Jan 01; 72(1):52-7. PubMed ID: 14962263
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.